

19 December 2022



The Nifty previous session ended 0.83% up at 18420.45. It opened flat followed by minor recovery in the end towards ending in red. Broader chart pattern suggesting this recovery may find sellers on rise. Hence, staying cautious on rise around 18500 levels is advised. Chart pattern suggesting range bound oscillation with a negative bias in the price band of 18200-18500 is likely. However, downtrend likely to continue even below 18200 towards 17800 levels.

On the Nifty hourly chart, direction of the RSI suggesting the Benchmark Index likely to find sellers on rise around 18500 levels. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; intraday recovery may again find sellers on rise, considering the bearish candle on the weekly. Massive resistance is placed in the price range of 18500-18550 levels. Hence, staying cautious on rise is advised.

Nifty Crucial Supports & Resistances-

Supports- 18200, 18130 Resistances- 18500, 18550

Open Positional Calls-

T+15 INST POSITIONAL SELL-

| Fut Segment | ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

| Fut Segment | HDFC BANK @ 1620-1640, TGT- 1530, Closing SL- above 1680

T+15 INST POSITIONAL BUY-

| Cash Segment | PAGE IND @ 46500-45500, TGT- 49500, Closing SL- below 44000

T+15 INST POSITIONAL SELL-

| Fut Segment | SBIN @ 610-615, TGT- 575, Closing SL- above 635

T+15 INST POSITIONAL SELL-

| Fut Segment | CAN BANK @ 330-335, TGT- 295, Closing SL- above 355

T+15 INST POSITIONAL SELL-

| Fut Segment | M&M @ 1320-1340, TGT- 1230, Closing SL- above 1380

T+5 BUY-

| Cash Segment | TECH MAHINDRA @ 1025-1020, TGT- 1060, Closing SL- below 1000

Nifty Intraday Chart



Market in Retrospect

The Indian benchmark indices ended higher, snapping a two-day losing streak on Monday.

Nifty index ended 0.83% higher at 18,421 points. The broader markets represented by the Nifty 500 Index ended 0.76% higher, ending at 15,755. Among the sectorial indices, Nifty Consumption was the top gainer gaining 1.60%, followed by Nifty Auto was higher by 1.59%. Nifty IT was the top loser losing by 0.51%.

Adani Ports & SE was the top gainer, gaining by 3.77%, followed by M&M and Eicher Motors which gaining by 3.12% & 2.96%. TCS was the top loser, losing by 1.18%, followed by Infosys and ONGC which losing by 0.98% & 0.95%.

Market Turnover (In Crore) 19-12-2022

Name	Last	Previous
NSE Cash	47194.36	65564.89
NSE F&O	12507945.78	14061380.91
BSE Cash	3,444.19	4,130.75
BSE F&O	*NA	132.92

FII Derivatives Flow (In Crore) 19-12-2022

Instrument	Purchase	Sale	Net
Index Future	3198.30	2042.49	1155.81
Index Option	895821.49	892237.83	3583.66
Stock Future	9368.07	7601.65	1766.42
Stock Option	10944.93	10708.56	236.37

Institutional Flow (In Crore) 19-12-2022

Institution	Purchase	Sale	Net
FII	5276.33	5814.43	-538.10
DII	4616.32	3928.94	687.38

*Data not updated till 6:45PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Adani Ports & SE	3.77	1.31	5205837	4727077
M&M	3.12	2.11	2767603	1975749
Eicher Motors	2.96	2.06	890120	582640
Power Grid	2.67	1.55	5819147	6455645
Adani Enterprises	2.37	1.46	1643404	1119479

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Sun Pharma	0.57	0.06	1547342	1846560
Tata Motors	0.85	0.93	9809103	16506760
ONGC	0.95	2.42	10635055	14239800
Infosys	0.98	2.58	6222740	7044617
TCS	1.18	2.57	2120965	1647662

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	61806.19	468.38	0.76	0.52	0.23	4.51	8.41
Nifty	18420.45	151.45	0.83	0.41	0.62	4.53	8.45
BSE M Cap	25912.52	173.31	0.67	1.00	3.09	1.55	5.58
BSE S Cap	29602.03	85.28	0.29	0.21	2.96	1.55	4.03
Nifty MC 100	32186.85	176.75	0.55	0.94	4.11	2.17	7.51
BSE Auto	29768.45	490.38	1.67	0.59	1.70	0.61	23.25
BSE Capgoods	34798.91	263.84	0.76	0.32	4.27	7.24	24.03
BSE FMCG	16713.36	234.97	1.43	0.33	4.95	4.87	24.96
BSE Metal	20630.25	186.32	0.91	0.15	4.16	9.01	7.57
BSE Oil&Gas	20629.65	162.95	0.80	0.09	4.31	5.71	16.52
BSE Healthcare	23094.34	16.80	0.07	1.23	1.33	1.87	5.75
BSE Power	4540.28	42.48	0.94	0.01	3.27	13.07	28.37
BSE Realty	3528.93	26.03	0.74	1.47	1.23	1.60	6.54
BSE ConsDur	40049.02	291.32	0.73	0.88	1.71	4.79	5.45
BSE Bank	49367.86	264.70	0.54	0.65	1.69	5.42	21.93
BSE IT	28633.12	159.77	0.55	1.88	3.96	4.51	20.38

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.52	0.04	1.05	2.57	8.10	0.81	150.95
UK	3.45	0.13	3.76	7.90	6.64	10.11	355.07
Brazil	5.98	0.12	2.01	4.37	2.43	0.84	28.98
Japan	0.26	0.00	0.39	0.79	2.41	0.78	420.41
Australia	3.53	0.08	2.26	4.50	2.16	3.94	122.76
India	7.30	0.02	0.28	1.04	0.14	0.86	13.84
Switzerland	1.30	0.02	1.25	8.18	25.10	16.55	545.36
Germany	2.20	0.05	2.23	13.46	9.24	21.88	682.01

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.70	0.17	0.20	0.20	1.04	3.54	8.21
USD Index	104.56	0.14	0.13	0.54	2.21	4.71	8.28
YUAN	6.97	0.00	0.00	0.05	2.74	0.44	8.58
GBP	1.22	0.00	0.28	0.71	3.04	6.57	7.76
EUR	1.06	0.00	0.18	0.65	3.54	5.80	5.98
YEN	136.34	0.26	0.19	0.98	4.25	5.04	16.67

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1560.00	32.00	2.09	12.55	31.20	0.45	34.43
Baltic Dirty	2078.00	14.00	0.67	1.33	12.14	39.28	158.78
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32920.46	281.76	0.85	1.66	2.45	6.13	6.91
Nasdaq	10705.41	105.12	0.97	2.72	3.95	7.19	29.43
S&P 500	3852.36	43.39	1.11	2.08	2.85	1.22	16.63
FTSE100	7368.99	36.81	0.50	1.03	0.22	1.83	1.36
CAC40	6480.58	28.91	0.45	2.54	2.45	6.93	6.43
DAX	13940.46	49.89	0.36	2.54	3.39	8.90	10.23
Mexico IPC	49630.14	287.80	0.58	2.84	3.76	6.06	5.25
Brazil Bovespa	102855.7	881.99	0.85	4.34	5.52	8.02	4.05
Russian RTS	991.33	46.92	4.52	8.92	13.54	22.08	37.35
Japan Nikkei	27237.64	289.48	1.05	2.17	2.37	1.20	4.58
Hang Seng	19352.81	97.86	0.50	0.57	7.56	4.24	16.56
Taiwan Index	14433.32	95.23	0.66	1.23	0.49	0.05	18.97
Shanghai Comp	3107.12	60.74	1.92	2.26	0.32	0.27	14.46
KOSPI	2352.17	7.85	0.33	0.88	3.78	0.15	22.05
Malaysia KLCI	1477.09	1.45	0.10	0.18	1.92	1.76	1.66
Jakarta Comp	6779.70	32.50	0.48	0.67	4.27	5.78	2.69
Philippine SE	6414.27	82.23	1.27	2.60	0.36	0.36	12.11
Thai Exch	1618.20	0.81	0.05	0.30	0.05	0.82	1.43

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	74.54	0.38	0.51	2.05	6.76	12.90	5.38
BRENT Crude	79.43	0.45	0.57	1.92	8.79	9.32	14.67
Natural Gas	6.23	0.37	5.61	5.42	7.24	22.84	54.98

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1794.81	1.99	0.11	0.77	2.54	7.11	0.17
Silver(\$/Ounce)	23.25	0.04	0.18	0.19	11.10	18.93	4.01
Aluminium	2337.10	7.65	0.33	4.50	2.09	3.04	12.01
Copper	8234.00	19.00	0.23	3.21	0.32	4.64	13.55
Zinc	3048.50	132.25	4.16	7.23	0.42	4.26	12.02
Lead	2155.25	8.75	0.41	1.68	0.53	15.01	7.20

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	166.25	1.85	1.13	0.48	7.19	22.84	28.05
Cotton	82.17	0.25	0.31	3.50	1.92	11.69	5.43
Sugar	20.37	0.28	1.39	5.11	1.60	17.27	11.68
Wheat	754.25	0.75	0.10	0.07	8.24	10.90	2.68
Soybean	1476.25	7.50	0.51	0.73	3.00	0.48	20.22

Car sales in India set to hit record 3.8 million units in 2022

India's automakers are projected to end this calendar year with sales of 3.8 million passenger vehicles (PVs), exceeding the previous record by more than 400,000 vehicles, driven by sustained demand and improved component supplies that helped them step up production. With Indians shopping for cars and sports utility vehicles like never before, PV sales this year are set to increase by nearly a fourth - the fastest growth among major global economies - compared with 2021. Sales in the first 11 months of this year have already topped the previous annual record of 3.39 million units set in 2018. The estimated sales growth for this year is 23%.

NTH to offer EV battery testing at Mumbai & Kolkata centres from next fiscal

Anticipating a rise in demand for electric vehicles (EV), the government's National Testing House (NTH) on Monday said it will offer testing services for EV batteries and charging systems at its Mumbai and Kolkata centres from the next fiscal. Currently, the Manesar-based International Centre for Automotive Technology and the Pune-based Automatic Research Association of India (ARAI) are the two agencies in the country providing testing services for EVs and their batteries. The National Testing House (NTH) is preparing to offer testing services for EV batteries and charging systems at its Kolkata headquarters and Mumbai regional centre from the next fiscal. The NTH Mumbai and Kolkata centres were chosen because the maximum number of EV makers are located in Pune/Mumbai, while the maximum number of manufacturers of EV batteries are present in Kolkata. Srivastava said and added good quality products can be made if testing labs are located near the manufacturing units. Imported equipment used in EV making can also be tested at these two NTH centres. Already, the Bureau of Indian Standards (BIS) has come out with performance standards for EV batteries in order to ensure the safety of consumers.

Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug

Dr Reddy's Laboratories Ltd has successfully completed the Phase 1 study of its proposed biosimilar of Tocilizumab to be used in the treatment of rheumatoid arthritis in adults. The company's Tocilizumab biosimilar candidate 'DRL_TC' successfully met its primary and secondary endpoints in a Phase I study. This Phase I study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of the company's Tocilizumab biosimilar candidate in comparison to reference products. Dr Reddy's is developing the proposed Tocilizumab biosimilar as both subcutaneous and intravenous formulations.

Glenmark Pharma gets USFDA nod for generic drug

Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic nifedipine hydrochloride capsules used to treat high blood pressure and to control angina. The approval granted by the US Food & Drug Administration (USFDA) is for nifedipine hydrochloride capsules of strengths 20 mg and 30 mg. These are the generic version of Cardene capsules 20 mg and 30 mg of Chiesi USA. These will be distributed in the US by Glenmark Pharmaceuticals Inc, USA. For the 12-month period ended October 2022, the Cardene capsules 20 mg and 30 mg achieved annual sales of approximately USD 10.9 million.

KEC International bags new orders worth Rs 1,313 crore

Global infrastructure engineering, procurement, and construction (EPC) major KEC International on Monday said that it has secured new orders of Rs 1,313 crore across its various businesses. The business has secured orders for transmission and distribution projects in India, East Asia Pacific and SAARC. These are for 220 kV GIS substation for a refinery project in India, 500 kV transmission line in Thailand and another 132 kV transmission line and associated substations in Nepal. The company also said its business has secured a large order for a 500 megawatt (mw) solar PV project in India.



CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

[illegible]

Domestic Events

- No events

Global Events

- BOJ Interest Rate Decision.
- The U.S. Housing Starts for November 2022.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com